A U.S. biotechnology company focused on cancer treatments, Parabilis Medicines (PBLS.US), has completed an upsized U.S. IPO priced above its marketed range. Combined with a concurrent private placement, the offering has raised nearly $745 million in total.

The company stated on Tuesday that its IPO priced 33.5 million shares at $20 per share, raising approximately $670 million. Earlier on Tuesday, the company had increased the offering size and raised its price range from $17–$19 to the final pricing of $20.

The announcement also indicated that concurrently with the IPO, Regeneron Pharmaceuticals agreed to purchase nearly $75 million worth of Parabilis stock (approximately 4.17 million shares) at $18 per share. According to regulatory filings, Regeneron had previously announced a research collaboration with Parabilis in May, paying an upfront $50 million and committing to purchase shares in Parabilis's next equity financing round.

Based on the IPO price and the outstanding shares listed in the filing, the biotech company's market valuation is approximately $2.4 billion. Prior to the upsizing on Tuesday, demand for the IPO had reached about 10 times the shares initially offered.

Filings show that as of the end of the 2025 fiscal year, Parabilis reported a net loss of $145.9 million, with year-end cash and cash equivalents of $27.7 million. The previous fiscal year's net loss was $117.9 million, with cash of $47.3 million.

Parabilis Medicines was founded in 2015 and specializes in developing treatments for various cancers and rare tumors. The company intends to use the IPO proceeds to advance its lead candidate drug, zolucatetide, into later-stage clinical trials.

The bookrunners for the offering included Leerink Partners, Bank of America, Evercore, Guggenheim Securities, and LifeSci Capital. The company's shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol PBLS.

Focus on Future Growth

This emerging clinical-stage biotech firm, focused on cancer therapy, is not yet generating revenue from commercialized drugs. Its core growth strategy hinges on future commercial revenue from drug approvals, expansion of treatment indications, development of its platform pipeline, and external licensing partnerships.

Rationale for the IPO Financing

The logic behind the IPO financing centers on three key points: advancing zolucatetide into later-stage clinical trials, expanding the application of its Helicon platform for 'undruggable' targets, and realizing platform value through partnerships with major pharmaceutical companies. For instance, the company has already entered a strategic collaboration with Regeneron to combine the Helicon peptide platform with Regeneron's antibody capabilities to develop novel Antibody-Helicon™ Conjugates.

Clinical Trial Progress

In its primary clinical trial for desmoid tumors, 38 patients have been enrolled and treated with zolucatetide. Among 25 patients with sufficient follow-up for efficacy evaluation, all 25 (100%) showed tumor shrinkage. Furthermore, among 19 patients who completed two post-baseline scans, 14 (74%) achieved an objective response according to RECIST 1.1 criteria.

The company plans to initiate a Phase 3 registration trial for desmoid tumors in the first half of 2027. It is also evaluating the potential of zolucatetide as a treatment for the orphan disease Familial Adenomatous Polyposis (FAP).

Prior Financial Backing

Parabilis Medicines has previously secured backing from Wall Street financial giants Fidelity and RA Capital, having raised nearly $1 billion through private financings. Its most recent round was a Series F financing in January, which raised over $300 million.